You have read all your free articles, to continue reading subscribe to read the rest of this content.
Nordic Nanovector provides an update on PARADIGME, its ongoing Phase 2b trial of Betalutin in 3rd-line relapsed/refractory follicular lymphoma. Despite COVID has the company seen a significant improvement in the enrolment rate from approximately two to approximately five patients per month, it stAlready a subscriber Login You have read all…
Moberg Pharma announced that the first patient has been included in a randomized controlled phase II study with BUPI, a novel topical formulation for the treatment of oral pain. The aim is to confirm the promising results gained from several smaller pilot studies and to evaluate if bupivaAlready a subscriber…
The company announces that the final patient has been enrolled in the LYMRIT 37-05 clinical trial of Betalutin (177Lu-satetraxetan-lilotomab) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not eligible for stem cell transplantation. “We are delighted to have reached Already a subscriber Login You have read all your free…
Immunicum has announced continued compelling survival data from its phase I/II-study in metastatic renal cell carcinoma. The data showed a median survival for patients with poor prognosis (five patients) currently at 13 months compared to the expected median survival of 8-9 months for patients Already a subscriber Login You have read all…
